RxDoctor Payments Data

Crystal Neises, APRN

Family · Cassville, MONPI 1770020141

Payments from drug & device makers

$681in general payments, 2019–2025

Across 37 payments — averaging $18.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$118
  • AbbVie$68
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$63
  • Merck$54
  • Otsuka America Pharmaceutical, Inc.$51
  • Novartis$49
  • plus $279 from 11 others

What the payments were for

  • Food & beverage$681100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$681 in reported general payments places this provider in the 60th percentile of 3,812 family providers in Missouri.

See all family providers in Missouri

Medicare billing

Part B allowed, 2024
$1,482
Medicare patients
50
Services billed
62

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide36$45,468
EliquisApixaban37$25,385
JardianceEmpagliflozin28$21,790
JanuviaSitagliptin Phosphate32$19,631
MounjaroTirzepatide16$16,946
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$15,103
Repatha SureclickEvolocumab27$14,261
SymbicortBudesonide/Formoterol Fumarate46$11,595
LinzessLinaclotide16$10,801
SavellaMilnacipran Hcl20$9,427
XareltoRivaroxaban14$7,047
Incruse ElliptaUmeclidinium Bromide19$6,468
Breo ElliptaFluticasone/Vilanterol15$6,429
TrintellixVortioxetine Hydrobromide13$6,407
Fluticasone-SalmeterolFluticasone Propion/Salmeterol38$3,352

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Novolog Mix 70-30$118$46,25448 claims
Boehringer IngelheimJardiance$34$21,79028 claims
AbbVieLinzess, Savella, Synthroid$68$21,19758 claims
MerckJanuvia$54$19,63132 claims
Lilly USA, LLCMounjaro, Humulin 70-30$33$18,10927 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,812 family providers in Missouri.

Other family in Cassville

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →